glp-1 and vyvanse Studies highlight promise risks of new weight-loss drugs Mounjaro And Vyvanse

doi: 10.1126/science.abo7649 77

For most patients, the first 3 months provide a good indication of how well the medication is working, though weight loss continues beyond that timeframe

There are now four proven therapies that can reduce the risk of kidney disease progression in people with type 2 diabetes: reninangiotensinaldosterone system (RAAS) blockade, with either ACE inhibitors or angiotensin receptor blockers (ARBs) sodium-glucose cotransporter-2 (SGLT-2) inhibitors nonsteroidal mineralocorticoid receptor antagonists (MRAs) glucagon-like peptide-1 (GLP-1) receptor agonists

First, which H

Rapid weight loss without adequate protein intake, resistance training, and proper nutrition can lead to both muscle and fat loss